Baseline Inflammatory Burden Index Predicts Primary Resistance to Combinations of ICIs With Chemotherapy in Patients With HER-2-Negative Advanced Gastric Cancer
Journal of Gastric Cancer · 2025
DOI: 10.5230/jgc.2025.25.e14 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastric Cancer, 2025. Verfasst von Tingting Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Drug Resistance, Neoplasm, Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research Foundation of Education Department of Anhui Province of China, Natural Science Foundation of Bengbu College.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Combinations of immune checkpoint inhibitors (ICIs) and chemotherapy have become the standard first-line treatment for human epidermal growth factor receptor 2 (HER-2)-negative advanced gastric cancer. However, primary resistance remains a challenge, with no effective biomarkers available for its prediction. This retrospective study explores the relationship between the baseline inflammatory burden index (IBI) and primary resistance in such context. MATERIALS AND METHODS: We analyzed 62 patients with HER-2-negative advanced gastric cancer who received ICIs and chemotherapy as their first-line treatment. The IBI was calculated as follows: C-reactive protein (mg/L) × neutrophil count (10³/mm³)/lymphocyte count (10³/mm³). Based on disease progression within 6 months, patients were categorized into the primary resistant or the control group. We compared baseline characteristics and IBI scores between the groups and assessed the predictive value of the IBI using the receiver operating characteristic curve. Both univariate and multivariate binary logistic regression analyses were conducted to identify factors influencing primary resistance. RESULTS: Nineteen patients were included in the primary resistance group, and forty-three patients were included in the control group. The IBI was significantly higher in the resistant group compared to the control group (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
- Department of Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, China. wzsh51103@bbmc.edu.cn.
ORCID-Profile: Tingting Wang, Huihui Zeng, Ting Hu, Junhao Zhang, Zishu Wang
Förderung
- Research Foundation of Education Department of Anhui Province of China
- Natural Science Foundation of Bengbu College
Zitieren
APA
Wang, T., Zeng, H., Hu, T., Zhang, J., & Wang, Z. (2025). Baseline Inflammatory Burden Index Predicts Primary Resistance to Combinations of ICIs With Chemotherapy in Patients With HER-2-Negative Advanced Gastric Cancer. Journal of Gastric Cancer. https://doi.org/10.5230/jgc.2025.25.e14
Vancouver
Wang T, Zeng H, Hu T, Zhang J, Wang Z. Baseline Inflammatory Burden Index Predicts Primary Resistance to Combinations of ICIs With Chemotherapy in Patients With HER-2-Negative Advanced Gastric Cancer. Journal of Gastric Cancer. 2025. doi:10.5230/jgc.2025.25.e14
BibTeX
@article{Wang2025,
author = {Wang, Tingting and Zeng, Huihui and Hu, Ting and Zhang, Junhao and Wang, Zishu},
title = {Baseline Inflammatory Burden Index Predicts Primary Resistance to Combinations of ICIs With Chemotherapy in Patients With HER-2-Negative Advanced Gastric Cancer},
journal = {Journal of Gastric Cancer},
year = {2025},
doi = {10.5230/jgc.2025.25.e14}
}
EUVIMED